Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck

Cancer Research

Volumn 56, Issue 22, 1996, Pages 5198-5204

  Leonard, Charles E ^a   Chan, Daniel C ^b   Chou, T C ^c   Kumar, Rita ^b   Bunn, Paul A ^b  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RADIOSENSITIZING AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; COMBINED MODALITY THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; HEAD AND NECK NEOPLASMS; HUMANS; PACLITAXEL; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TUMOR CELLS, CULTURED;

EID: 0029822071     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, R. C., Ettinger, D. S., Armstrong, D. K., and Donehower, R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasia. Ann. Intern. Med., 3: 273-279, 1989.
2. Thigpen, J. T., Blessing, J., and Belf, H. Phase II trial of taxol as second-line therapy for ovarian carcinoma: a Gynecologic Oncology Group study Proc. Am. Soc. Clin. Oncol., 9: 604, 1990.
3. Holmes, F. A., Walters, R. S. D., Theriault, R. L., Forman, A. D., Newton, L. K., Raber, M. N., Buzdar, A. U., Frye, D. K., and Hortobagyi, G. N. Phase II trial of taxol: an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83: 1797-1805, 1991.
4. Forastiere, A., Adams, G., Neuberg, D., and Taylor, S. Phase II trial of taxol in head and neck cancer: an Eastern Oncology Cooperative Oncology Group Study. Second National Cancer Institute Workshop on Taxol and Taxus, September 23-24, Alexandria, VA, 1992.
5. Ajani, J. A., Ilson, D. H., Daugherty, K., Pazdur, R., Lynch, P. M., and Kelsen, D. P. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J. Natl. Cancer Inst., 86: 1086-1091, 1994.
6. McGuire, W. P., Blessing, J. A., Moore, D., Lentz, S. S., and Photopulos, G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol., 14: 792-795, 1996.
7. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
8. Steren, A., Sevin, B. U., Ferras, J., Angioli, R., Nguyen, H., Guerra, L., Koechli, O., and Averette, H. E. Taxol sensitizes human ovarian cancer cells to radiation Gynecol. Oncol., 48: 252-258, 1993.
9. Tishler, R. B., Geard, C. R., Hall, E., and Schiff, P. B. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res., 52: 3495-3497, 1992.
10. Tishler, R. B., Schibb, P. B., Geard, C. R., and Hall, E. J. Taxol: a novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys., 22: 613-617, 1992.
11. Choy, H., Rodriguez, F. F., Koester, S., Hilsenbeck, S., and Von Hoff, D. D. Investigation of taxol as a potential radiation sensitizer. Cancer (Phila.), 71: 3774-3778, 1993.
12. Liebman, J., Cook, J. A., Fisher, J., Teague, D., and Mitchell, J. B. In vitro studies of taxol as a radiation sensitizer in human tumor cells J. Natl. Cancer Inst., 86: 441-446, 1994.
13. Rodriguez, M., Sevin, B. U., Perras, J., Nguyen, H. N., Pham, C., Steren, A. J., Koechli, O. R., and Averette, H. E. Paclitaxel: a radiation sensitizer of human cervical cancer cells. Gynecol Oncol., 57: 165-169, 1995.
14. Lokeshwar, B., Ferrell, S. M., and Block, N. L. Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late stage malignancy Anticancer Res., 15: 93-98, 1995.
15. Stromberg, J. S., Lee, Y. J., Armour, E. P., Martinez, A. A., and Corry, P. M. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer (Phila.), 75: 2262-2268, 1995.
16. Geard, C. R., and Jones, J. M. Radiation and taxol effects on synchronized human cervical carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys., 29: 565-569, 1994.
17. Erlich, E., Potkul, R., McCall, A., Walter, S., and Vaughn, A. Taxol is only a weak radiosensitizer of human cervical cell lines Int. J. Radiat. Oncol. Biol. Phys., 30: 172, 1994.
18. Milas, L., Hunter, N. R., Mason, K. A., Kurdoglu, B., and Peters, L. J. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res., 54: 3506-3510, 1994.
19. Milas, L., Hunter, N. R., Mason, K. A., Milross, C. G., Saito, Y., and Peters, L. J. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res., 55: 3564-3568, 1995.
20. Hennequin, C., Giocanti, N., and Favaudon, V. Interaction of ionizing radiation with paclitaxel (taxol) and docetaxel (taxotere) in HeLa and SQ20B cells. Cancer Res., 56: 1842-1850, 1996.
21. Chou, T-C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul. 22: 27-55, 1984.
22. Chou, T-C., Rideout, D., Chou, J., and Bertino, J. R. Chemotherapeutic synergism, potentiation and antagonism In R. Dulbecco (ed.), Encyclopedia of Human Biology, Vol 2, pp 371-379. San Diego, CA Academic Press, 1991.
23. Chou, T-C. The median-effect principle and the combination index for quantitation of synergism and antagonism In T-C. Chou and D. C. Rideout (eds.), Synergism and Antagonism in Chemotherapy, pp. 61-102. San Diego, CA, Academic Press, 1991.
24. Chou, T-C., Motzer, R. J., Tong, Y., and Bosl, G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against teratocarcinoma cell growth a rational approach to clinical protocol design. J. Natl. Cancer Inst., 86: 1517-1524, 1994.
25. Chou, J., and Chou, T-C. Dose-effect analysis with microcomputers, quantitation of ED50, LD50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics (Manual and Software) Cambridge, United Kingdom: Biosoft, 1987.
26. Chou, J., and Chou, T-C. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: T-C. Chou and D. C. Rideout (eds.), Synergism and Antagonism in Chemotherapy, pp 223-244. San Diego, CA: Academic Press, 1991.
27. Krishan, A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol., 66: 188-193, 1975.
28. 2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
29. Donehower, R. C., and Rowinsky, E. K. Anticancer drugs derived from plants. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 4, pp. 409-417. Philadelphia J. B. Lippincott Co., 1993.
30. Longnecker, S. M., Donehower, R. C., Cates, A. E., Chen, T-L., Brundrett, R. B., Grochow, L. B., Ettinger, D. S., and Colvin, M. High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial Cancer Treat. Rep., 71: 53-59, 1987.